Drug co-administration often affects the patient response to warfarin through various mechanisms. We describe here five HIV-1-infected patients on treatment with warfarin in whom the use of raltegravir was associated with a favourable outcome.
MajerusFW, BrozeGJJr, MiletichJP, TollefsenDM. Anticoagulant, thrombolytic, and antiplatelet drugs. In: HardmanJG, LimbirdLE, MolinoffPB., eds. Goodman and Gilman's the Pharmacological Basis of Therapeutics, 9th edn.New York: McGraw-Hill, 1996; 1341–59
2.
AithalGP, DayCP, KestevenPJ, DalyAK.Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.Lancet1999; 353: 717–9.
3.
DionisioD, MininniS, BartolozziD, EspertiF, VivarelliA, LeonciniF.Need for increased dose of warfarin in HIV patients taking nevirapine.AIDS2001; 15: 277–8.
4.
BonoraS, LanzafameM, D'AvolioA.Drug interactions between warfarin and efavirenz or lopinavir-ritonavir in clinical treatment.Clin Infect Dis2008; 46: 146–7.
5.
HondaH, GatanagaH, MatsumuraJ.Favorable use of non-boosted fosamprenavir in patients treated with warfarin, Int J STD AIDS2009; 20: 441
6.
IwamotoM, KassahunK, TroyerMD.Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation.J Clin Pharmacol2008; 48: 209–14.
7.
Schöller-GyüreM, KakudaTN, RaoofA.Clinical pharmacokinetics and pharmacodynamics of etravirine.Clin Pharmacokinet2009; 48: 561–74.
8.
HeSM, ZhouZW, LiXT, ZhouSF.Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development.Curr Med Chem2011; 18: 667–713.
